Project 172371
Endobiotics glucuronidation: a novel therapeutic avenue for metabolic and endocrine diseases
172371
Endobiotics glucuronidation: a novel therapeutic avenue for metabolic and endocrine diseases
$300,000
Project Information
| Study Type: | Unclear |
| Research Theme: | Biomedical |
Institution & Funding
| Principal Investigator(s): | Barbier, Olivier |
| Institution: | Université Laval |
| CIHR Institute: | Nutrition, Metabolism and Diabetes |
| Program: | |
| Peer Review Committee: | New Investigators C |
| Competition Year: | 2008 |
| Term: | 5 yrs 0 mth |
Abstract Summary
Glucuronidation is an enzymatic reaction very well studied for the role its plays in drug elimination. However, this reaction also affects a wide variety of endogenous substance. The aim of our research program is to determine whether controlling the elimination of specific endogenous compounds through the use of novel drugs can be of therapeutic value in the treatment of various pathologies such as liver diseases, cardiovascular diseases or prostate cancer.
No special research characteristics identified
This project does not include any of the advanced research characteristics tracked in our database.
Keywords
Cardiovascular Diseases
Endobiotics Metabolism
Gene Regulation
Hormonal Diseases
Liver Diseases
Molecular Pharmacology